ConocoPhillips delivered its best week in months after the August 6 earnings print, and the Street wasted no time in marking up its view — four separate analyst target raises arrived in five trading days, even as the stock has now moved well past several of those revised levels.
The analyst upgrade cycle is the standout this week. UBS raised its target to $153 on August 12 while maintaining its Buy rating, and Susquehanna moved to $161 the day before — both firms resetting higher after COP rose 2.3% on the day and 6.8% on the week to close at $125.92. Wells Fargo and Truist also lifted targets, though Truist's Hold-rated $130 target now sits only fractionally above the current price. The consensus mean has moved to $144.70, implying roughly 15% headroom from here — a narrower cushion than the ~17% gap flagged before the earnings print but still a constructive setup. The direction of travel on the Street is clearly upward; even the skeptics are re-anchoring their numbers. The bull case centers on disciplined capital allocation, a strong free cash flow profile, and a leadership transition to incoming CEO Tim O'Brien that analysts appear comfortable with. Bears point to a history of capex overruns and the argument that the stock's commodity-linked fundamentals don't offer much torque on the upside when crude moves.
Positioning data backs the constructive mood rather than challenging it. Short interest has fallen sharply — bears trimmed exposure by nearly 9% in a single session on August 11, bringing shorts down to just 1.4% of the free float, from around 2.1% in late July. Borrowing costs dropped to 0.29%, their lowest level in 30 days, and share availability is essentially unconstrained. There is no meaningful short-side pressure here, and the direction of travel since the August 6 print has been bears stepping back rather than piling in. Options positioning is modestly more defensive than its recent average — the put/call ratio is running at 0.75, about 1.2 standard deviations above the 20-day mean of 0.72 — but this is a far cry from the elevated hedging that preceded the July print. Call buying still leads the options market with a comfortable margin; the slight uptick in relative put demand looks more like normal profit-protection after a 15% monthly rally than any serious conviction about downside.
Among peers, COP's 6.8% weekly gain stands out. OXY was the nearest comparison, up 7.2%, while CVX gained 3.3% and EOG was essentially flat. APA led the group with 13.5% on the week, while MUR fell nearly 7%. The divergence within the group suggests stock-specific reactions to individual earnings prints rather than a simple crude-price tide lifting all boats.
On valuation, the multiple expansion has been steady. The P/E has drifted up by around half a turn over the past week to 13.0x, and EV/EBITDA has risen modestly to 5.7x. Neither figure looks stretched for a large-cap E&P with COP's balance sheet quality. Factor scores reflect the same picture: analyst recommendation spread ranks in the 89th percentile of the ORTEX universe, dividend score sits at 74, and the short score has eased to 30.6 — its lowest reading in the past 10 days, consistent with a name where bears are retreating rather than building.
Insider activity warrants a brief note. The 90-day net figure shows a large gross outflow, driven almost entirely by outgoing Chairman and CEO Ryan Lance, who sold over 620,000 shares between March 20 and March 31 at prices in the $127–$133 range. Those sales were made ahead of his planned departure and reflect the leadership transition already in progress. There has been no material selling activity since then.
The next scheduled earnings event is November 5. With targets freshly reset and the stock trading above its pre-August consensus, the conversation between now and then is likely to centre on crude price direction, progress under the new CEO, and whether the buyback pace holds through the back half of the year.
See the live data behind this article on ORTEX.
Open COP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.